Figure 4.
Transcytosis of oxaliplatin-loaded immunoliposomes across an in vitro model of the BBB. (A) Oxaliplatin-loaded immunoliposomes functionalized with either OX26 or isotype IgG antibodies were administrated to a monolayer of primary BCECs derived from young rats in Transwell co-culture with astrocytes. After incubation, the ‘BCEC’ and ‘brain’ fractions were isolated for subsequent ICP-MS analysis to quantify the platinum content. (B) In the BCEC fraction, OX26 immunoliposomes yielded a higher platinum content compared to the isotype IgG immunoliposomes (p = 0.0035). (C) In the brain fraction, the platinum content of the isotype IgG immunoliposome-treated group was significantly higher compared to that treated with OX26 immunoliposomes (p = 0.0017). Data are presented as mean + SEM (n = 7–8), and the p-values depicted were derived from a one-way ANOVA with Tukey’s multiple comparisons post hoc test. BCEC: Brain capillary endothelial cell. ICP-MS: Inductively-coupled plasma mass spectrometry. OxPt: Oxaliplatin.